US5762954A - Isosorbide dinitrate-containing patch using a mixed adhesive - Google Patents

Isosorbide dinitrate-containing patch using a mixed adhesive Download PDF

Info

Publication number
US5762954A
US5762954A US08/700,418 US70041896A US5762954A US 5762954 A US5762954 A US 5762954A US 70041896 A US70041896 A US 70041896A US 5762954 A US5762954 A US 5762954A
Authority
US
United States
Prior art keywords
adhesive
isosorbide dinitrate
layer
based adhesive
containing patch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/700,418
Other languages
English (en)
Inventor
Takao Fujii
Makoto Iwata
Minoru Furuya
Michisuke Ohe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Assigned to TEIJIN LIMITED reassignment TEIJIN LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUJII, TAKAO, FURUYA, MINORU, IWATA, MAKOTO, OHE, MICHISUKE
Application granted granted Critical
Publication of US5762954A publication Critical patent/US5762954A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Definitions

  • the present invention relates to an isosorbide dinitrate (ISDN)-containing patch. More specifically, the present invention relates to a patch in which an adhesive composition having isosorbide nitrate incorporated in a mixed adhesive comprising a silicone-based adhesive and polyvinyl acetate-based adhesive at a specified mixing ratio is formed on a flexible support and has excellent sustained release properties and good percutaneous absorption.
  • ISDN isosorbide dinitrate
  • Drugs such as isosorbide dinitrate are commonly known to be absorbed percutaneously, and numerous products have already been developed as patches containing these drugs. It is indicated, in, for example, Japanese Unexamined Patent Publication No. 57-116011, that pressure-sensitive adhesives such as silicone-based, rubber-based and acrylic-based pressure-sensitive adhesives are preferable as pressure-sensitive adhesives used in these patches.
  • pressure-sensitive adhesives such as silicone-based, rubber-based and acrylic-based pressure-sensitive adhesives are preferable as pressure-sensitive adhesives used in these patches.
  • Okuni, et.al. reported that with respect to patches containing ISDN, in comparing acrylic-based, silicone-based and rubber-based pressure-sensitive adhesives, the percutaneous absorption of these three are roughly equal.
  • an object of the present invention is to provide a patch with minimal skin irritation and favorable percutaneous absorption by designing an adhesive having excellent compatibility with isosorbide dinitrate.
  • an object of the present invention is to provide a sustained release patch with minimal skin irritation and favorable percutaneous absorption.
  • an object of the present invention is to provide a patch with minimal skin irritation, favorable percutaneous absorption even without using percutaneous absorption promoters, and favorable adhesive strength.
  • the inventors of the present invention achieved the present invention as a result of earnest research to solve the above-mentioned problems.
  • silicone-based adhesive (A) examples include adhesives composed of the condensation reaction product of straight-chain dimethylpolysiloxane having a terminal silanol functional group having the two-dimensional structure indicated below in formula (I): ##STR1## wherein Me: --CH 3
  • R' --OH, --CH 3
  • R and/or R' may be substituted with other alkyl groups, vinyl groups, alkoxy groups or aryl groups and so forth provided that they have almost no effect on the adhesive properties.
  • silicone-based adhesive (A) of the present invention represented with the above-mentioned formula (I) include, for example, Bio-PSA (registered trademark) 355, Bio-PSA (registered trademark) Q7-2920, Bio-PSA (registered trademark) Q7-4501 manufactured by Dow-Corning, and PSA6574 of Toshiba Silicone.
  • silicone-based adhesive (A) of the present invention even if the chemical structure of the skeleton and substitution groups in the above-mentioned formula (I) are partially changed with conventional known groups such as carboxyl groups, alkyl groups, vinyl groups and phenyl groups, the percutaneous absorption and adhesive properties of said silicone-based adhesive (A) are practically unaffected.
  • this type of silicone-based adhesive can be used, for example, in ordinary pharmaceutical applications.
  • said silicone-based adhesive can be used alone or as a mixture of 2 or more types.
  • silicone-based adhesives (A) in the present invention preferably include adhesives represented with the above-mentioned formula (I), for example Bio-PSA355, Bio-PSAQ7-2920, Bio-PASQ7-4501 and PSA6574, and more preferably Bio-PSAQ7-4501 and PSAQ7-2920 since they are resistant to peeling, result in less pain when removed, and have a suitable degree of tackiness.
  • adhesives represented with the above-mentioned formula (I) for example Bio-PSA355, Bio-PSAQ7-2920, Bio-PASQ7-4501 and PSA6574, and more preferably Bio-PSAQ7-4501 and PSAQ7-2920 since they are resistant to peeling, result in less pain when removed, and have a suitable degree of tackiness.
  • the polyvinyl acetate-based adhesive (B) in the present invention refers to, for example, vinyl acetate homopolymer, copolymers of vinyl acetate and (meth)acrylate alkyl ester and/or (meth)acrylic acid, and copolymers of vinyl acetate and vinyl ethers such as vinyl butyl ether.
  • the copolymerization ratio of vinyl acetate must be at least 50% by weight of the polymer.
  • (meth)acrylate alkyl esters are preferably alkyl esters of (meth)acrylic acid having a mean carbon number of 3 to 14, examples of which include butyl (meth)acrylate, amyl (meth)acrylate, hexyl (meth)acrylate, heptyl (meth)acrylate, octyl (meth)acrylate, nonyl (meth)acrylate, decyl (meth)acrylate and 2-ethylhexyl (meth)acrylate.
  • polyvinyl acetate-based adhesive (B) of the present invention preferably include copolymers of vinyl acetate and (meth)acrylate alkyl esters and/or (meth)acrylic acid, and particularly preferably copolymers of vinyl acetate and alkyl esters of (meth)acrylic acid having a mean carbon number of 3 to 14, especially, for example copolymers of 2-ethylhexyl (meth)acrylate and (meth)acrylic acid.
  • the copolymerization ratio of the polymer in this case is such that the ratio of vinyl acetate is at least 50% by weight, preferable examples of which include those in which the copolymerization ratio of vinyl acetate to (meth)acrylate alkyl ester and/or (meth)acrylic acid is 50:50 to 90:10, and preferably 60:40 to 80:20.
  • a copolymerization ratio of approximately 70:30 is particularly preferable.
  • a mixture system of this silicone-based adhesive (A) and polyvinyl acetate-based adhesive (B) is used.
  • the advantages of this combination include extremely high percutaneous absorption of ISDN, and a low level of skin irritation.
  • silicone-based adhesives are known to be used in ISDN-containing patches.
  • mixing is actually hardly ever performed with the exception of the case of rubber-based adhesives in which its properties are inherently not demonstrated unless it is mixed.
  • the patch of the present invention using a mixed adhesive of silicone-based adhesive (A) and polyvinyl acetate-based adhesive (B) exhibits good percutaneous absorption that is equal to or better than patches obtained by using other preferable adhesives such as acrylic-based adhesives.
  • adhesive strength to the skin is also favorable.
  • mixed adhesive obtained by mixing different types of adhesives form a so-called matrix-island structure, resulting in the appearance of special characteristics in adhesion with the skin and release of ISDN.
  • silicone-based adhesive (A) is an adhesive represented with the above-mentioned formula (I) and, specifically, is Bio-PSA (registered trademark) 355, Bio-PSA (registered trademark) Q7-2920 or Bio-PSA (registered trademark) Q7-4501 made by Dow-Corning, or PSA6574 made by Toshiba Silicone, and in which polyvinyl acetate-based adhesive (B) is a homopolymer of vinyl acetate, a copolymer of vinyl acetate and (meth)acrylate alkyl ester and/or (meth)acrylic acid, or a copolymer of vinyl acetate and a vinyl ether such as vinyl butyl ether, and the copolymerization ratio of vinyl acetate is at least 50% by weight, particularly a copolymer of vinyl
  • the ratio of ISDN (C) to the above-mentioned mixed adhesive is such that ISDN is blended or contained so that the relationship of the weight of ISDN (C) to the total weight of silicone-based adhesive (A) and polyvinyl acetate-based adhesive (B) ((A+B):C) being 90:10 to 60:40 is satisfied. If the ratio of ISDN (C) is less than 10, the effect of the drug is inadequate, while if it exceeds 40, the amount of crystallized ISDN in the adhesive increases causing a decrease in the adhesive strength of the resulting adhesive and a corresponding decrease in the flexibility of the patch. Moreover, even if the amount of ISDN is increased beyond 40, since the percutaneous absorption per unit area of ISDN does not increase, the availability of ISDN decreases.
  • silicone-based adhesive (A) and polyvinyl acetate-based adhesive (B) are dissolved or dispersed in a single solvent or a mixture of solvents such as ethyl acetate, hexane, chloroform, xylene, toluene, hexane, acetone or methanol, ISDN (C) is mixed into the resulting adhesive solution or dispersion, or the resulting adhesive solution or dispersion is coated on a piece of separating paper or separating film, without mixing ISDN (C) or without mixing an adequate amount of ISDN (C), so that the thickness after drying will be a prescribed thickness, namely 5-100 ⁇ m, drying the resulting paper or film, and sufficiently removing the solvent by evaporation to obtain an adhesive layer (A') that contains ISDN (C) or an adhesive layer (A') that does not contain or does not sufficiently contain ISDN (C).
  • a single solvent or a mixture of solvents such as ethyl acetate, hexan
  • an adhesive layer (A') containing ISDN (C) is obtained by mixing ISDN (C) into an adhesive solution, followed by coating and drying under mild conditions
  • a patch can be obtained by laminating said adhesive layer (A') containing ISDN (C) (corresponding to adhesive layer (d) described later) with a laminate comprising film layer (a), adhesive layer (B')(b) and fabric (c), in which ISDN being dropped into said fabric (C) in advance as necessary using a method to be described later in order to ensure an adequate content of ISDN, and consequently attaching adhesive layer (A')(d) to a flexible support, and then cutting to a desired size.
  • a particularly preferable patch of the present invention is obtained in the case of coating and drying an adhesive solution without mixing ISDN or a sufficient amount of ISDN into this adhesive solution.
  • a sufficient amount refers to the amount which exhibits pharmaceutical effects.
  • the amount of residual solvent in the patch decreases, and more specifically, as the amount of residual solvent approaches 100 ppm or less, and preferably 50 ppm or less, the skin irritation of the patch also decreases.
  • ISDN is a sublimating drug, if ISDN is contained in advance and then heated, the ISDN sublimates and results in the problem of a loss of content.
  • an adhesive layer (A') is first obtained that does not contain ISDN or does not sufficiently contain ISDN by coating an adhesive solution or dispersion without mixing ISDN or without mixing a sufficient amount of ISDN therein, and then adhering the desired ISDN onto the adhesive layer (A') by dropping, spraying, coating or immersing in an ISDN solution, in which ISDN is dissolved at a high concentration in a highly volatile solvent such as acetone, methanol, ethanol or ethyl acetate, either directly or indirectly by means of a film, knitted fabric, woven fabric, non-woven fabric or a composite material of these.
  • said ISDN is dispersed in said adhesive layer (A') by allowing it to stand for a long time or heating and so forth to obtain a patch.
  • isopropyl myristate When using an absorption promoter, isopropyl myristate is particularly preferable as an absorption promoter. When using isopropyl myristate, it should be used in the amount of 0.01 to 5 parts by weight to 1 part by weight of ISDN (C).
  • absorption promoters and dispersion assistants examples include surfactants such as sodium lauryl sulfate, sodium dodecylbenzene sulfonate, sodium alkyldiphenylether disulfonate, dioctyl sulfo-succinate and polyoxyalkylphenylethersulfate ammonium salt; alcohols such as glycerine, diethylene glycol, propylene glycol, polyethylene glycol and higher aliphatic alcohols; dimethylsulfoxide and alkylmethyl derivatives; salicylic acid, urea, dimethylacetoamide, dimethylformamide, lanolin, allantoin, squalene, carbopore, diisopropyl adipate, pyroglutamic lauryl ester, ethyl laurate, methyl nicotinate, sorbitol and pyrolidone derivatives, such as dodecylpyrolidone,
  • surfactants such as sodium
  • the adhesive layer (A') comprising an adhesive composition containing silicone-based adhesive (A), polyvinyl acetate-based adhesive (B) and ISDN (C) is formed on a flexible support.
  • polyesters such as polyethylene terephthalate, polyolefins such as polyethylene and polypropylene, polyamides such as Nylon 6, and copolymers of ethylene and vinyl acetate. Polyester is preferable in terms of stability and safety.
  • the resulting patch has a high degree of stability and its handling is favorable.
  • the thickness of the film be 0.5 to 10 ⁇ m, and the fabric has 8 to 100 g/m 2 unit area weight, and a polyester film having a thickness of 0.5 to 4.9 ⁇ m and a polyester fabric having 5 to 60 g/m 2 unit area weight is particularly preferable.
  • said patch comprises:
  • outermost layer is (a), and the other layers in the order of (a), (b), (c), (d) and (e) are laminated on that layer, which (e) is discarded in use.
  • Layer (a) is a polyester film layer having a thickness of 0.5 to 4.9 ⁇ m, and the ultra-thin polyester film developed and sold by Teijin Ltd. for use in condensers (trade name: Teijin Tetoron Film Type F) is particularly preferable for the film.
  • Layer (b) is an adhesive layer having a thickness of about 5 to 40 ⁇ m, and is composed of, for example, a silicone-based adhesive, acrylic-based adhesive, rubber-based adhesive, polyvinyl acetate-based adhesive or an ethylene-vinyl acetate copolymer-based adhesive and so forth either alone or as a mixture.
  • (b) is an adhesive layer having a thickness of about 10 to 25 ⁇ m and the adhesive is a rubber-based adhesive.
  • (c) is a polyester fabric having 5 to 60 g/m 2 unit area weight.
  • (d) is the adhesive layer (A') of the present invention, as described above, composed of a mixture of silicone-based adhesive (A) and polyvinyl acetate-based adhesive (B), wherein the weight ratio of A and B is 85:15 to 15:85 and the thickness is 10 to 60 ⁇ m.
  • (e) is a polyester film-based separating film coated with a fluorine resin and having a thickness of 30 to 100 ⁇ m.
  • ISDN (C) is mainly present in the adhesive layer (A')(d), it may also be present in adhesive layer (B')(b) and fabric (c).
  • the polyester film of film layer (a) preferably has a thickness within the range of 0.5 to 4.9 ⁇ m in terms of strength, ease of handling, skin rash and sealing. If the thickness is less than 0.5 ⁇ m, there are cases in which strength, ease of handling and so forth are inadequate, while if the thickness exceeds 4.9 ⁇ m, there are cases of problems with respect to skin retention and skin rash. A thickness of about 1.0 to 3.5 ⁇ m is particularly preferable in terms of strength, ease of handling, retention and skin rash.
  • a fabric having the above-mentioned unit area weight is obtained, with respect to, for example, the thickness of the fibers that compose a polyester hollow fiber fabric like that described later, fabrics having the above-mentioned unit area weight are preferable in the case of fibers of about 20 to 75 denier, examples of which include fabric having about 12 to 16 g/m 2 unit area weight with about 20 denier fibers, fabric having about 17 to 24 g/m 2 unit area weight with about 50 denier fibers, and fabric having 25 to 30 g/m 2 unit area weight with about 75 denier fibers.
  • examples of the form of the fabric in this case include knitted fabric, woven fabric and non-woven fabric, knitted fabric is particularly preferable.
  • Preferable examples of combinations of these components (a) through (d) include those in which (a) is a polyester film having a thickness of about 1.0 to 3.5 ⁇ m, (b) is an adhesive layer composed of a rubber-based adhesive having a thickness of about 10 to 25 ⁇ m, (c) is a polyester fabric having 10 to 40 g/m 2 unit area weight, and particularly 10 to 25 g/m 2 , and particularly a fabric that is a woven fabric having about 12 to 16 g/m 2 unit area weight composed of 20 denier polyester fibers, and (d) is the above-mentioned mixed adhesive layer (A') having a thickness of about 25 to 45 ⁇ m.
  • an adhesive layer (B')(b) not sufficiently containing ISDN and an adhesive layer (A')(d) are manufactured, a laminate is produced by adhering film layer (a) and fabric (c) via adhesive layer (B')(b), ISDN dissolved in a solvent such as acetone is incorporated into the fabric portion of said laminate by dropping, spraying or immersion, after which the ISDN solvent is removed by evaporation, and then adhesive layer (A')(d) is pressed.
  • the patch obtained in this manner is provided with separating film layer (e).
  • ISDN can be adequately dispersed in adhesive layer (A')(d) by allowing the patch obtained in the above manner to stand for a long time or by heating.
  • ISDN-containing patches are normally used after cutting to a size of 10-100 cm 2 , said cutting may be performed before or after heating.
  • the measurement method of blood ISDN concentration, and preparation of the polyvinyl acetate-based adhesive and fabric sample used in the examples are as indicated below.
  • ISDN is extracted using 4 ml of n-hexane followed by concentration and the addition of 100 ⁇ l of ethyl acetate to the concentrate to obtain the sample.
  • the amount of ISDN in the sample is assayed by GC-ECD.
  • Copolymers composed of 2-ethylhexyl acrylate and so forth were used in addition to vinyl acetate (Wako Pure Chemical Industries Ltd.). This polymer was synthesized according to the following method.
  • the reaction product was placed in flask for condensation polymerization equipped with a fractionating column followed by the addition of stabilizer in the form of 0.090 parts of a 56% aqueous solution of orthophosphoric acid and condensation polymerization catalyst in the form of 0.135 parts of antimony trioxide.
  • stabilizer in the form of 0.090 parts of a 56% aqueous solution of orthophosphoric acid and condensation polymerization catalyst in the form of 0.135 parts of antimony trioxide.
  • the reaction was continued for 100 minutes under high vacuum.
  • the final internal pressure was 0.39 mmHg
  • the intrinsic viscosity of the resulting copolymer was 0.402
  • the softening point was around 200° C.
  • the copolymer was formed into chips in accordance with a usual process.
  • These chips were dried in accordance with a usual manner and then spun in accordance with a usual method using a spinneret having an arc-shaped opening in which two circular slits measuring 0.05 mm wide and 0.6 mm in diameter were closed to produce a hollow fiber having a ratio of outer diameter to inner diameter of 2:1 (hollow rate: 25%).
  • the resulting hollow fiber had fine pores dispersed over the entire cross-sectional surface of said hollow fiber and arranged in the direction of the fiber. At least a portion of said fine pores were connected to the hollow portion of the fiber.
  • the yarn was a 300 denier/24 filaments, and was drawn to an elongation factor of 4.2 times in accordance with a usual manner to obtain a multifilament yarn of 71 denier/24 filaments. A single filament of this multifilament yarn had a diameter of 11 ⁇ m.
  • This multifilament yarn was formed into a Merrius knitted fabric, and, after scouring and drying in accordance with routine methods, the fabric was treated with 1% aqueous caustic soda at boiling temperature for 2 hours to obtain a knitted fabric having an alkaline loss rate of 20%.
  • the resulting knitted fabric was drawn by 1.5 times in the longitudinal direction and heat set by applying heat for 1 minute at 100° C. to obtain a knitted fabric having 17 g/m 2 unit area weight, namely the fabric sample.
  • Bio-PSA registered trademark 355 (solid portion: 18.5%) manufactured by Dow-Corning was used for silicone-based adhesive (A), while the solution obtained in (2) above was used for polyvinyl acetate-based adhesive (B).
  • silicone-based adhesive (A) and polyvinyl acetate-based adhesive (B) were changed as described in Table 1, and both components were mixed well to obtain a mixed dope.
  • Two types of adhesive layers were then obtained having thicknesses after drying on a fluorine-based separating film of 15 ⁇ m (adhesive layer (B')(b)) and 40 ⁇ m (adhesive layer (A')(d)) with respect to the respective levels.
  • adhesive layer (b) was first pressed onto film (a), and the fabric sample (c) was pressed onto the free surface of adhesive layer (B')(b).
  • an acetone solution of ISDN (C) was continuously dropped onto the free surface of the fabric sample so that the amount of ISDN (C) would be 8 g per 1 m 2 of the fabric sample.
  • adhesive layer (A')(d) was pressed onto the free surface of said fabric to obtain a laminate.
  • a separating film coated with a white, fluorine-based separating agent having a thickness of 50 ⁇ m was attached to the side on which adhesive layer (A')(d) was not pressed onto the fabric. After cutting to a size of about 7 cm ⁇ 7 cm (7.1 cm ⁇ 7.1 cm), the resulting laminate was heated at 65° C.
  • Blood samples were collected before application, 5 hours after application and 24 hours after application.
  • the ISDN concentrations in the blood of each sample were measured and Cmax and AUC values were calculated from the resulting blood concentrations.
  • the quality of adherence to the skin was also investigated. Those results are shown in Table 1.
  • PVAC means polyvinyl acetate.
  • the acrylic-based adhesive was synthesized in accordance with the following method. 90 parts of 2-ethylhexyl acrylate, 7 parts of methyl methacrylate, 3 parts of acrylic acid, 1 part of benzoyl peroxide and 100 parts of ethyl acetate were charged into a reaction vessel equipped with a reflux condenser and stirrer. Polymerization was continued for 12 hours with slowly stirring at 60° C. under a nitrogen. The polymerization conversion rate was 99.9%. 300 parts of ethyl acetate were added to the resulting polymer solution followed by adjustment of the solid concentration to about 20%.
  • Patches (Examples 8 and 9) were obtained in a similar manner as in Example 1 using a polyethylene terephthalate film (Teijin Tetoron Film Type F, etc.) having a thickness of 2.5 ⁇ m as film (a), a rubber-based adhesive having a thickness of 30 ⁇ m as adhesive layer (b), a mixed adhesive of silicone-based adhesive (A) and polyvinyl acetate-based adhesive (B) having a thickness of 30 ⁇ m as adhesive layer (d) (wherein, the polyvinyl acetate-based adhesive was composed from ingredients described in Table 3), and a fabric sample obtained from a knitted fabric having a fiber thickness of 50 denier and 20 g/m 2 unit area weight as fabric (c).
  • a polyethylene terephthalate film Teijin Tetoron Film Type F, etc.
  • a rubber-based adhesive having a thickness of 30 ⁇ m as adhesive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US08/700,418 1994-02-28 1995-02-28 Isosorbide dinitrate-containing patch using a mixed adhesive Expired - Fee Related US5762954A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2969994 1994-02-28
JP6-029699 1994-02-28
PCT/JP1995/000318 WO1995022970A1 (en) 1994-02-28 1995-02-28 Patch containing isosorbide dinitrate and prepared by using adhesive mixture

Publications (1)

Publication Number Publication Date
US5762954A true US5762954A (en) 1998-06-09

Family

ID=12283367

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/700,418 Expired - Fee Related US5762954A (en) 1994-02-28 1995-02-28 Isosorbide dinitrate-containing patch using a mixed adhesive

Country Status (15)

Country Link
US (1) US5762954A (de)
EP (1) EP0748626B1 (de)
JP (1) JP3162079B2 (de)
KR (1) KR100354499B1 (de)
CN (1) CN1144481A (de)
AT (1) ATE204166T1 (de)
AU (1) AU689225B2 (de)
CA (1) CA2184389A1 (de)
DE (1) DE69522212T2 (de)
DK (1) DK0748626T3 (de)
ES (1) ES2158937T3 (de)
GR (1) GR3037058T3 (de)
NZ (1) NZ281334A (de)
PT (1) PT748626E (de)
WO (1) WO1995022970A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017580B1 (ru) * 2008-02-15 2013-01-30 Тоо "Казнаномед" Способ увеличения периода полувыведения изосорбида динитрата при коронарной недостаточности

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0900565B1 (de) * 1997-01-07 2004-10-27 Teijin Limited Isosorbiddinitrat enthaltendes pflaster
HK1043317B (en) * 1999-04-01 2006-02-10 Alza Corporation Transdermal drug delivery devices comprising a polyurethane drug reservoir
KR100439658B1 (ko) * 2001-06-23 2004-07-12 제일약품주식회사 이소소르비드 디니트레이트를 활성성분으로 하는경피흡수제제 및 그 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4956181A (en) * 1987-05-08 1990-09-11 Eastman Kodak Nitrate therapy for angina pectoris
US5300291A (en) * 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61100520A (ja) * 1984-10-22 1986-05-19 Sekisui Chem Co Ltd 経皮投与型テ−プ状医薬品
JP3064402B2 (ja) * 1990-11-19 2000-07-12 森本 雍憲 硝酸イソソルビド含有貼付剤
JP3197039B2 (ja) * 1991-08-08 2001-08-13 積水化学工業株式会社 テープ製剤
JPH05156328A (ja) * 1991-12-09 1993-06-22 Nkk Corp 高炉異常炉況解析装置
JP3081413B2 (ja) * 1993-06-03 2000-08-28 帝三製薬株式会社 混合系粘着剤を用いた硝酸イソソルビド含有貼付剤の製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4956181A (en) * 1987-05-08 1990-09-11 Eastman Kodak Nitrate therapy for angina pectoris
US5300291A (en) * 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017580B1 (ru) * 2008-02-15 2013-01-30 Тоо "Казнаномед" Способ увеличения периода полувыведения изосорбида динитрата при коронарной недостаточности

Also Published As

Publication number Publication date
DE69522212D1 (de) 2001-09-20
EP0748626B1 (de) 2001-08-16
ES2158937T3 (es) 2001-09-16
JP3162079B2 (ja) 2001-04-25
KR100354499B1 (ko) 2003-01-06
CA2184389A1 (en) 1995-08-31
DE69522212T2 (de) 2002-05-23
GR3037058T3 (en) 2002-01-31
KR970701042A (ko) 1997-03-17
ATE204166T1 (de) 2001-09-15
EP0748626A1 (de) 1996-12-18
DK0748626T3 (da) 2001-10-08
EP0748626A4 (de) 1997-11-12
NZ281334A (en) 1997-08-22
AU1824795A (en) 1995-09-11
AU689225B2 (en) 1998-03-26
PT748626E (pt) 2002-02-28
WO1995022970A1 (en) 1995-08-31
CN1144481A (zh) 1997-03-05

Similar Documents

Publication Publication Date Title
US5225199A (en) Pharmaceutical plasters
US5589192A (en) Gel pharmaceutical formulation for local anesthesia
CA2248167C (en) Patch containing isosorbide dinitrate
DE3231400C2 (de)
KR100610185B1 (ko) 경피흡수형제제
US20040057985A1 (en) Transdermal therapeutic system comprising the active ingredient oxybutynin
CN1045355A (zh) 一种用于生产以含毒扁豆碱作为活性组分的经皮治疗系统的方法
JPWO1998030210A1 (ja) 硝酸イソソルビド含有貼付剤
EP1385490B1 (de) Haftkleber auf basis von ethylen-vinylacetat-copolymeren und klebharzen, für medizinische verwendungszwecke
US5762954A (en) Isosorbide dinitrate-containing patch using a mixed adhesive
JPH0959152A (ja) 硝酸イソソルビド含有貼付剤
DE10035891A1 (de) Medizinischer Haftkleber mit einer zweiphasigen Klebermatrix aus Polyacrylaten und Polyaminsalzen
JP3081413B2 (ja) 混合系粘着剤を用いた硝酸イソソルビド含有貼付剤の製造方法
JPWO1995022970A1 (ja) 混合系接着剤を用いた硝酸イソソルビド含有貼付剤
JP2945244B2 (ja) 酢酸ビニール系粘着剤を用いた硝酸イソソルビド含有貼付剤
JPH0959153A (ja) 硝酸イソソルビド含有貼付剤の製造方法
JPH06345639A (ja) 混合系粘着剤を用いた硝酸イソソルビド含有貼付剤
JPH0717851A (ja) （メタ）アクリル酸エステル系粘着剤を用いた薬剤含有貼付剤
JPS6059209B2 (ja) 複合製剤
JPH0791193B2 (ja) エストラジオール含有貼付剤
HK1103965A1 (en) Tulobuterol adhesive patch

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEIJIN LIMITED, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FUJII, TAKAO;IWATA, MAKOTO;FURUYA, MINORU;AND OTHERS;REEL/FRAME:008195/0074

Effective date: 19960815

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20060609